summary,sentiment,keywords
" On June 23, Google reportedly reduced its investment in its smart TV division, specifically cutting the budget for Google TV and Android TV by 10%. The reduction amounts to tens of millions of dollars from an annual budget that was previously under $500 million . The shift aligns with Google’s prioritization of Gemini, as the company increases its budget for AI efforts .  Alphabet Inc. (NASDAQ:GOOGL) offers various products and platforms through Google Services, Google Cloud, and Other Bets segments . While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk .",negative,"nasdaq, google, stocks, googl, android"
" Alphabet Inc. (NASDAQ:GOOGL) has been one of the worst-performing mega-cap stocks in 2025 . Its shares have been weighed down by weak cloud performance and antitrust action . Cramer’s previous comments have speculated that recent strong quarterly performance was primarily due to success of its AI video application .  Some AI stocks hold greater promise for delivering higher returns and have limited downside risk . If you are looking for an extremely cheap AI stock, see our free report on thebest short-term AI stock .",negative,"stocks, stock, nasdaq, alphabet, googl"
 OpenAI has quietly designed a rival to compete with Microsoft Office and Google Workspace . ChatGPT would allow people to collaborate on documents and communicate via chat in ChatGpt . Launching these features would allow OpenAI to compete more directly against Microsoft .  Microsoft Stock (MSFT) as a ‘Key Beneficiary of AI Adoption’ Top analyst views Microsoft Stock as a key beneficiary of AI adoption .,neutral,"openai, microsoft, chatgpt, msft, office"
" Bootstrap Bio, created about 18 months ago, is working on technology to change the DNA in an embryo . Altering those cells to make genetically modified children is intended to eliminate inherited diseases or enhance desirable traits . Scientists and ethicists said the technology known as editing is a step toward creating designer babies .  “germline editing” is unproven and potentially dangerous . It could have grave consequences if a flaw is introduced into a days-old embryo, with the changes affecting every cell and stage of development . Experts fear it could usher in a new era of eugenics and foster further inequality .  Bootstrap Bio was founded by GeneSmith and kman on LessWrong, a forum popular in Silicon Valley . Gene_Smith said the company hired a chief science officer, opened a lab and pivoted its work . The company's focus is now working on gene editing the DNA of adults .  Among Bootstrap Bio's early investors are Simone and Malcolm Collins, a couple known for advocating for higher birth rates . The Collinses have been linked to billionaire and fellow pronatalist Elon Musk . The pair said they would consider using germline editing for some of their own embryos to minimize health risks for future children .  Even laboratory work on germline editing is highly regulated in the US, researchers have been making progress on the technology . Still, it’s not ready for prime time, a researcher at Oregon Health and Science University says . More research is needed to determine whether technology is safe and effective in clinical context .  Chinese researcher He Jiankui was sentenced to three years in prison and a lifelong ban from working in reproductive technology . He plans to relocate to Austin to continue working on embryonic genetic editing in a new lab . Federal law prohibits the agency from accepting any application involving genetic edits to reproductive cells, including embryos .  Bootstrap Bio’s future business plans included a plan to begin human trials in 2026 or 2027 in Honduras, a place where the company could potentially avoid US regulations . There is, however, no outright ban on editing reproductive cells in the lab when done using private funding .  Gap’s last-Ditch, Tariff-Addled Turnaround Push How to Steal a House Luxury Counterfeiters Keep Outsmarting the Makers of $10,000 Handbags .",neutral,"embryo, genetically, gene, bootstrap, embryonic"
" Alphabet Inc. has recently been on Zacks.com's list of the most searched stocks . Shares of this company have returned -3.6% over the past month versus the Zacks S&P 500 composite's +5.1% change .  Alphabet is expected to post earnings of $2.12 per share for the current quarter, representing a year-over-year change of +12.2% . Over the last 30 days, the Zacks Consensus Estimate remained unchanged . For the next fiscal year, the consensus earnings estimate of $9.53 for the fiscal year indicates a year over-18.5% change .  $10.18 indicates a change of +6.8% from what Alphabet is expected to report a year ago . Over the past month, the estimate has remained unchanged . The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold)  Alphabet reported revenues of $76.49 billion in the last reported quarter, representing a year-over-year change of +13.2% EPS of $2.81 for the same period compares with $1.89 a year ago . The company beat consensus estimates in each of the trailing four quarters .  The Zacks Value Style Score (part of the Zacks Style Scores system) pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F . Alphabet is graded C on this front, indicating that it is trading at par with its peers .  Alphabet may perform in line with the broader market in the near term . However, its Zacks Rank #3 does suggest that it may perform better than expected .",negative,"earnings, zacks, alphabet, stocks, estimates"
